Analysis of SARS-CoV-2 Ig seroprevalence in Northern Ireland. - Supplementary material

Michelle K Greene¹, Peter Smyth¹, Andrew English^{2,3}, Joseph McLaughlin², Magda Bucholc⁴, Janice Bailie⁵, Julie McCarroll⁵, Margaret McDonnell⁶, Alison Watt⁷, George Barnes⁸, Mark Lynch⁹, Kevan Duffin¹⁰, Gerard Duffy¹¹, Claire Lewis¹², Jacqueline A James^{1,12,13}, Tom Ford¹⁴, Maurice O'Kane⁹, Taranjit Singh Rai², Anthony J Bjourson², Christopher Cardwell¹⁵, J Stuart Elborn¹⁶, David S Gibson², Christopher J Scott^{1*}

¹The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK

² Personalised Medicine Centre, School of Medicine, Ulster University, Londonderry, UK

³ School of Health and Life Sciences, Teeside University, Middlesbrough, UK

⁴ Intelligent Systems Research Centre, School of Computing, Engineering & Intelligent Systems, Ulster University, Londonderry, UK

⁵HSC R&D Division, Public Health Agency, Belfast, UK

⁶Department of Clinical Biochemistry, Belfast Health and Social Care Trust, Belfast, UK

⁷ Regional Virology Laboratory, Belfast Health and Social Care Trust, Belfast, UK

⁸Department of Clinical Biochemistry, South-Eastern Health and Social Care Trust, Dundonald, UK

⁹Department of Clinical Biochemistry, Altnagelvin Hospital, Western Health and Social Care Trust, Londonderry, UK

¹⁰Department of Clinical Biochemistry, Southern Health and Social Care Trust, Portadown, UK
¹¹Department of Clinical Biochemistry, Northern Health and Social Care Trust, Antrim, UK
¹²The Northern Ireland Biobank, Queen's University Belfast, Belfast, UK
¹³Regional Molecular Diagnostic Service, Belfast Health and Social Care Trust, Belfast, UK

1

¹⁴ Bacteriology Branch, Veterinary Sciences Division, AFBI, Belfast, UK

¹⁵Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK

¹⁶Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK

*Corresponding Author - **Christopher J. Scott** – Patrick G Johnston Centre for Cancer Research, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast BT9 7AE, U.K.; Email: <u>c.scott@qub.ac.uk</u>; Telephone: +44 (0)28 9097 2350

Supplementary Table 1. Overall estimates by time period.

	June/July 2020		Nov/D	ec 2020	June/July 2021			
	cases/total	estimate (95% CI/CrI)	cases/total	estimate (95% Cl/Crl)	cases/total	estimate (95% CI/CrI)		
Crude apparent proportion	43/1108	3.9% (2.9%, 5.4%)	64/1242	5.2% (4.0%, 6.5%)	290/2494	11.6% (10.4%, 13.0%)		
Standardised apparent proportion ¹	43/1108	3.6% (1.7%, 5.6%)	64/1238	5.2% (3.6%, 6.7%)	290/2493	12.9% (11.2%, 14.5%)		
Crude true proportion ²	43/1108	3.4% (1.6%, 5.2%)	64/1242	5.1% (3.2%, 7.1%)	290/2494	13.4% (11.4%, 15.7%)		
Standardised true proportion ³	43/1108	3.6% (1.8%, 5.8%)	64/1238	5.4% (3.7%, 7.5%)	290/2493	14.5% (12.5%, 16.7%)		

¹Based upon NI age (0-29,30-49,50-69,70+) and gender distribution, one individual missing gender. ²True proportion using Bayesian method (used by PHE England), credible intervals used instead of confidence intervals, assuming sensitivity of 79% (137/173) and specificity of 98% (699/707). ³True proportion using Bayesian method (used by PHE England), credible intervals used instead of confidence intervals, assuming sensitivity of 79% (137/173) and specificity of 98% (699/707) and standardised based upon NI age (0-29,20-49,50-69,70+) and gender distribution.

	COVID-19 cases/total (%)	P^1	Odds Ratio (OR) (95% CI)	Р	Adjusted ² OR (95% CI)	Р
June/July 2020	43/1108 (3.9%)		1.00 (ref. cat.)		1.00 (ref. cat.)	
Nov/Dec 2020	64/1242 (5.2%)	<0.001	1.35 (0.91, 2.00)	0.14	1.33 (0.89 <i>,</i> 1.99)	0.16
June/July 2021	290/2494 (11.6%)		3.26 (2.35 <i>,</i> 4.53)	< 0.001	3.09 (2.21, 4.31)	<0.001

Supplementary Table 2. Comparison of COVID-19 proportions by time period.

¹Chi-squared 2x3 P-value. ²Adjusting for trust, age and sex.

Supplementary Table 3. Sample characteristics by time period. Breakdown of total numbers of samples assayed (N) and percentage (%) according to Health and Social Care Trust, age group and gender across all three testing rounds.

	Round 1	Round 2	Round 3		
	June/July 2020	Nov/Dec 2020	June/July 2021		
	N (%)	N (%)	N (%)		
Health and Social Care Trust					
Belfast	223 (20.1%)	246 (19.8%)	499 (20.0%)		
Western	210 (19.0%)	248 (20.0%)	495 (19.8%)		
Southern	225 (20.3%)	248 (20.0%)	500 (20.0%)		
Northern	225 (20.3%)	250 (20.1%)	500 (20.0%)		
South Eastern	225 (20.3%)	250 (20.1%)	500 (20.0%)		
Age group					
0-29	74 (6.7%)	152 (12.3%)	341 (13.7%)		
30-49	185 (16.7%)	278 (22.4%)	585 (23.5%)		
50-69	394 (35.6%)	452 (36.5%)	850 (34.1%)		
70+	453 (41.0%)	357 (28.8%)	718 (28.8%)		
Gender					
Female	580 (52.5%)	682 (55.0%)	1417 (56.8%)		
Male	525 (47.5%)	559 (45.0%)	1076 (43.2%)		

Supplementary Table 4. Neutralising IgG reactivity summary of round 3 subpopulation. Reactivity

cut-off concentrations: * Spike =0.533 μ g/ml; ^{\$} S1 RBD =0.726 μ g/ml.

			0-29 years (n=35)		30-49 y	ears (n=80)	50-69 years (n=99)		70+ years (n=64)		Total (n=278)	
		Age (Median, IQR)	22	± 3.75	40.5	± 10	59	± 8	78	± 8.5	55	± 29.25
		Female (n, %)	17	48.6%	47	58.8%	54	54.5%	38	59.4%	156	56.1%
ACE2 pseudoneutralisation assay	wild type	Spike Reactive (n, %)*	19	54.3%	48	60.0%	73	73.7%	55	85.9%	195	70.1%
		S1 RBD Reactive (n, %) ^{\$}	27	77.1%	53	66.3%	72	72.7%	52	81.3%	204	73.4%
	S1 RBD variant ^{\$}	Alpha (B.1.1.7) Reactive (n, %)	28	80.0%	54	67.5%	69	69.7%	51	79.7%	202	72.7%
		Beta (B.1.351) Reactive (n, %)	16	45.7%	39	48.8%	65	65.7%	39	60.9%	159	57.2%
		Gamma (P.1) Reactive (n, %)	26	74.3%	47	58.8%	72	72.7%	49	76.6%	194	69.8%
	Spike variant [*]	Alpha (B.1.1.7) Reactive (n, %)	16	45.7%	44	55.0%	66	66.7%	53	82.8%	179	64.4%
		Beta (B.1.351) Reactive (n, %)	19	54.3%	40	50.0%	67	67.7%	51	79.7%	177	63.7%
		Gamma (P.1) Reactive (n, %)	17	48.6%	38	47.5%	70	70.7%	50	78.1%	175	62.9%
Roche Elecsys Anti-SARS-CoV-2		N-Antibody Reactive (n, %)	2	5.7%	5	6.3%	7	7.1%	1	1.6%	15	5.4%
IgG Assay		S-Antibody Reactive (n, %)	16	45.7%	53	66.3%	92	92.9%	58	90.6%	219	78.8%